American Shared Hospital Services Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 19% year-over-year to $8.4 million in Q2, driven by Direct Patient Services and international expansion. Cash flow and liquidity improved, but a $909,000 credit loss and refinancing needs remain key risks. Strategic investments and new financing support long-term growth.
-
The meeting covered Director elections, executive compensation, incentive plan approval, and auditor ratification. All proposals passed with a quorum present, and no shareholder questions were raised.
-
Revenue grew 15.9% year-over-year to $7.1 million, led by Direct Patient Care Services, with adjusted EBITDA up 18.4%. Leadership transition, new facility projects, and improved cash position support a positive outlook for continued growth.
Fiscal Year 2025
-
2025 saw stable revenue but a strategic shift to direct patient care, with strong growth in LINAC treatments and international operations. Challenges included contract expirations and lower margins, but decisive actions and new partnerships position the company for long-term growth.
-
Q3 2025 saw 2.5% revenue growth and improved margins, driven by direct patient care and new centers in Rhode Island and Mexico. Despite operational gains and a strong growth pipeline, share price remains low due to limited market exposure and thin trading.
-
Q2 2025 saw 16% sequential revenue growth, driven by direct patient services and international expansion, but year-over-year gross margin and net income declined due to higher costs and contract expirations. Strategic acquisitions and new centers position the company for long-term growth.
-
Q1 2025 revenue grew 17% year-over-year, led by direct patient services and international expansion, despite lower equipment leasing volumes. Gross margin and EBITDA declined due to higher costs and lower procedure volumes, but long-term growth prospects remain strong.
Fiscal Year 2024
-
Revenue grew 33% year-over-year to $28.3M in 2024, driven by acquisitions and international expansion. Direct patient services surged, while equipment leasing declined. Net income rose sharply due to a bargain purchase gain, despite Q4 losses from asset impairments.
-
Q3 2024 revenue grew 36% year-over-year to $6.99 million, driven by the Rhode Island acquisition and international expansion, though gross margin and Gamma Knife volumes declined. Integration costs and staffing transitions impacted profitability, but strong cash reserves and new growth initiatives support a positive long-term outlook.
-
Second quarter revenue grew 27% year-over-year to $7.1 million, driven by the Rhode Island acquisition and international expansion. Net income reached $3.6 million, including a $3.7 million after-tax gain from the acquisition, while cash reserves remained strong at $14.5 million.